MLYS
Price
$10.00
Change
-$0.26 (-2.53%)
Updated
Jan 24, 04:09 PM (EDT)
Capitalization
510.63M
47 days until earnings call
PRME
Price
$3.19
Change
-$0.07 (-2.15%)
Updated
Jan 24, 04:14 PM (EDT)
Capitalization
427.58M
41 days until earnings call
Ad is loading...

MLYS vs PRME

Header iconMLYS vs PRME Comparison
Open Charts MLYS vs PRMEBanner chart's image
Mineralys Therapeutics
Price$10.00
Change-$0.26 (-2.53%)
Volume$200
Capitalization510.63M
Prime Medicine
Price$3.19
Change-$0.07 (-2.15%)
Volume$600
Capitalization427.58M
MLYS vs PRME Comparison Chart
Loading...
MLYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MLYS vs. PRME commentary
Jan 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLYS is a Hold and PRME is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 25, 2025
Stock price -- (MLYS: $10.26 vs. PRME: $3.26)
Brand notoriety: MLYS and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLYS: 95% vs. PRME: 66%
Market capitalization -- MLYS: $510.63M vs. PRME: $427.58M
MLYS [@Biotechnology] is valued at $510.63M. PRME’s [@Biotechnology] market capitalization is $427.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $360.23B to $0. The average market capitalization across the [@Biotechnology] industry is $2.41B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLYS’s FA Score shows that 1 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • MLYS’s FA Score: 1 green, 4 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, MLYS is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLYS’s TA Score shows that 2 TA indicator(s) are bullish while PRME’s TA Score has 3 bullish TA indicator(s).

  • MLYS’s TA Score: 2 bullish, 6 bearish.
  • PRME’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, PRME is a better buy in the short-term than MLYS.

Price Growth

MLYS (@Biotechnology) experienced а +8.00% price change this week, while PRME (@Biotechnology) price change was +13.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.81%. For the same industry, the average monthly price growth was +3.47%, and the average quarterly price growth was -1.20%.

Reported Earning Dates

MLYS is expected to report earnings on Mar 12, 2025.

PRME is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (+3.81% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MLYS($511M) has a higher market cap than PRME($428M). PRME YTD gains are higher at: 11.644 vs. MLYS (-16.653). MLYS has higher annual earnings (EBITDA): -168.35M vs. PRME (-207.13M). MLYS has more cash in the bank: 264M vs. PRME (176M). PRME has higher revenues than MLYS: PRME (800K) vs MLYS (0).
MLYSPRMEMLYS / PRME
Capitalization511M428M119%
EBITDA-168.35M-207.13M81%
Gain YTD-16.65311.644-143%
P/E RatioN/AN/A-
Revenue0800K-
Total Cash264M176M150%
Total DebtN/A41.2M-
FUNDAMENTALS RATINGS
PRME: Fundamental Ratings
PRME
OUTLOOK RATING
1..100
20
VALUATION
overvalued / fair valued / undervalued
1..100
73
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
64

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MLYSPRME
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 17 days ago
90%
Bearish Trend 17 days ago
86%
Momentum
ODDS (%)
Bearish Trend 17 days ago
81%
Bullish Trend 17 days ago
79%
MACD
ODDS (%)
Bearish Trend 17 days ago
89%
Bullish Trend 17 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 17 days ago
83%
Bullish Trend 17 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 17 days ago
85%
Bullish Trend 17 days ago
73%
Advances
ODDS (%)
Bullish Trend 19 days ago
89%
Bullish Trend 22 days ago
76%
Declines
ODDS (%)
Bearish Trend 17 days ago
88%
Bearish Trend 26 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 17 days ago
88%
Bearish Trend 17 days ago
90%
Aroon
ODDS (%)
Bearish Trend 17 days ago
86%
Bearish Trend 17 days ago
84%
View a ticker or compare two or three
Ad is loading...
MLYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FDGKX40.890.22
+0.54%
Fidelity Dividend Growth K
WCMGX29.330.14
+0.48%
First Trust WCM Focused Global Gr Inst
FRSLX28.050.10
+0.36%
Nuveen Mid Cap Growth Opps A
BEQGX34.940.12
+0.34%
American Century Equity Growth Inv
HSAFX9.470.02
+0.21%
Hussman Strategic Allocation

MLYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLYS has been loosely correlated with PLRX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if MLYS jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLYS
1D Price
Change %
MLYS100%
+0.69%
PLRX - MLYS
44%
Loosely correlated
+2.01%
RCKT - MLYS
42%
Loosely correlated
+5.73%
ABOS - MLYS
42%
Loosely correlated
-1.14%
PRME - MLYS
42%
Loosely correlated
+2.52%
RXRX - MLYS
41%
Loosely correlated
+0.53%
More

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+2.52%
CRSP - PRME
63%
Loosely correlated
+0.07%
BEAM - PRME
61%
Loosely correlated
-0.38%
NTLA - PRME
59%
Loosely correlated
+2.54%
RXRX - PRME
55%
Loosely correlated
+0.53%
ABCL - PRME
54%
Loosely correlated
-0.28%
More